Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMI347A)

Drug Name
Lamivudine Drug Info
Synonyms
lamivudine; 134678-17-4; Epivir; Zeffix; Heptovir; Epivir-HBV; Hepitec; Heptodin; BCH-189; 3TC; Heptivir; CIS-LAMIVUDINE; (-)-2'-Deoxy-3'-thiacytidine; 4-amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one; GR-109714X; 3'-Thia-2',3'-dideoxycytidine; (-)-BCH-189; Lamivudine [USAN:BAN:INN]; GR109714X; beta-L-3'-Thia-2',3'-dideoxycytidine; beta-L-2',3'-Dideoxy-3'-thiacytidine; (-)NGPB-21; 136891-12-8; 2',3'-Dideoxy-3'-thiacytidine; (-)-BCH 189; UNII-2T8Q726O95; HSDB 7155; GR 109714X; DTHC; LMV; Lamivir; Zefix; BCH 189; BCH189; BCH-790; DRG-0126; Epivir (TN); Epivir(TM); GG-714; HHA & 3TC; HHA & Lamivudine; Heptovir (TN); Lamivudine & GNA; Zeffix (TN); Epivir-HBV (TN); Lamivudine [USAN:INN:BAN]; Lamivudine (JAN/USP/INN); Lamivudine, (2S-cis)-Isomer; Beta-L-2',3'-Dideoxy-3'-thiacytidine; Beta-L-3'-Thia-2',3'-dideoxycytidine; Beta-L-(-)-2',3'-dideoxy-3'-thiacytidine & Sho-Saiko-To; (+/-)-(Cis)-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (+/-)-3TC; (+/-)-BCH-189; (+/-)-SddC; (-)-(2'R,5'S)-1-[2'-Hydroxymethyl-5'-(1,3-oxathiolanyl)]cytosine; (-)-1-((2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine; (-)-1-[(2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (-)-NGPB-21; (-)-SddC; (-)-beta-L-2',3'-Dideoxy-3'-thiacytidine; (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one; 2',3' Dideoxy 3' thiacytidine; 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (+/-)-(Cis); 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)-(2R,5S); 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)-(2R,5S) & Galanthus Nivalis Agglutinin (GNA); 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)-(2R,5S) & Hippeastrum hybrid agglutinin(HHA); 3TC & GNA; 3TC & SST; 3TC (AIDS INITIATIVE) (AIDS INITIATIVE); 3TC and NV-01; 3TC, Zeffix, Heptovir, Epivir, Epivir-HBV, Lamivudine; 4-Amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone; 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one; 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one; Efavirenz/lamivudine/tenofovir fumarate
Therapeutic ClassAnti-HIV Agents
Cross-matching ID
PubChem CID
60825
ChEBI ID
CHEMBL141
CAS Number
CAS 134678-17-4
TTD Drug ID
D07TQV
VARIDT Drug ID
DR00116
INTEDE Drug ID
DR0912
ACDINA Drug ID
D00347

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Drug metabolism 2.48 0.00e+0 78/151 (51.66%) DPYS;MPO;AOX1;...
Proximal tubule bicarbonate reclamation 2.11 0.00e+0 21/23 (91.3%) CA2;SLC4A4;AQP1;...
Parkinson disease 2.09 2.21e-3 176/249 (70.68%) TUBA1A;TXN;SLC6A3;...
Butanoate metabolism 2.08 1.66e-3 23/28 (82.14%) ACAT2;ACSM5;BDH2;...
Glyoxylate and dicarboxylate metabolism 2.02 1.32e-3 23/30 (76.67%) DLD;ACAT2;HAO2;...
Ribosome 2.01 1.10e-3 113/158 (71.52%) MRPS16;RPL36;RPL26;...
Oxidative phosphorylation 1.98 9.46e-4 93/133 (69.92%) SDHD;COX7B;COX5B;...
DNA replication 1.98 8.28e-4 34/36 (94.44%) PCNA;PRIM1;RPA3;...
One carbon pool by folate 1.93 1.47e-3 15/20 (75%) MTHFD1;SHMT1;DHFR;...
Glycine, serine and threonine metabolism 1.91 1.32e-3 31/40 (77.5%) DLD;BHMT;GATM;...
Proteasome 1.87 3.61e-3 44/46 (95.65%) PSME1;PSME2;PSMD4;...
Valine, leucine and isoleucine degradation 1.84 4.97e-3 42/48 (87.5%) DLD;ACAT2;AOX1;...
Tryptophan metabolism 1.79 9.17e-3 35/42 (83.33%) DLD;ACAT2;AOC1;...
Pyruvate metabolism 1.78 8.52e-3 41/47 (87.23%) DLD;ACAT2;MDH1;...
Synthesis and degradation of ketone bodies 1.77 9.71e-3 9/10 (90%) ACAT2;BDH2;ACAT1;...
Homologous recombination 1.74 1.28e-2 35/41 (85.37%) RBBP8;RPA3;TOPBP1;...
Retinol metabolism 1.72 1.52e-2 41/68 (60.29%) AOX1;DHRS9;CYP1A2;...
Propanoate metabolism 1.69 2.02e-2 30/34 (88.24%) DLD;ACAT2;ACAT1;...
Mineral absorption 1.68 2.30e-2 48/60 (80%) MT1E;MT1H;MT1F;...
Metabolism of xenobiotics by cytochrome P450 1.66 2.55e-2 49/77 (63.64%) GSTA1;CBR3;CYP1A2;...
Prion disease 1.66 2.46e-2 209/273 (76.56%) TUBA1A;SDHD;COX7B;...
Renin-angiotensin system 1.64 2.59e-2 20/23 (86.96%) CTSG;ENPEP;MME
Mismatch repair 1.63 2.59e-2 22/23 (95.65%) PCNA;RPA3;LIG1;...
Amyotrophic lateral sclerosis 1.62 2.81e-2 267/364 (73.35%) TUBA1A;SDHD;COX7B;...
Tyrosine metabolism 1.62 2.89e-2 30/36 (83.33%) TYRP1;AOX1;HPD;...
Fatty acid degradation 1.60 3.06e-2 40/43 (93.02%) ACAT2;ACAA2;ACAT1;...
Huntington disease 1.60 2.94e-2 233/306 (76.14%) TUBA1A;SDHD;COX7B;...
Bile secretion 1.60 2.89e-2 68/90 (75.56%) CA2;SLC4A4;AQP1;...
Nitrogen metabolism 1.59 3.24e-2 16/17 (94.12%) CA2;CPS1;CA4;...
Thermogenesis 1.58 3.40e-2 173/232 (74.57%) SDHD;COX7B;COX5B;...
Hypertrophic cardiomyopathy -1.66 4.62e-2 81/90 (90%) SGCG;ITGB3;CACNA2D2;...
Small cell lung cancer -1.66 4.26e-2 90/92 (97.83%) AKT1;ITGB1;FHIT;...
Cell adhesion molecules -1.68 4.09e-2 118/148 (79.73%) HLA-DRA;JAM3;CLDN3;...
GnRH secretion -1.68 3.85e-2 60/64 (93.75%) PLCB4;MAP2K2;AKT1;...
Toll-like receptor signaling pathway -1.68 3.98e-2 94/104 (90.38%) PIK3CB;CD40;LBP;...
Autophagy -1.70 3.78e-2 113/169 (66.86%) SUPT20H;ATG2B;SNAP29;...
Various types of N-glycan biosynthesis -1.70 3.99e-2 26/39 (66.67%) DDOST;RPN1;MGAT4C;...
Toxoplasmosis -1.72 3.46e-2 103/112 (91.96%) LAMC2;STAT1;CASP3;...
Osteoclast differentiation -1.72 3.59e-2 117/127 (92.13%) TREM2;PPARG;FOSL1;...
Allograft rejection -1.76 2.52e-2 32/38 (84.21%) HLA-F;HLA-DRB1;IL10;...
Malaria -1.77 2.52e-2 44/50 (88%) HBB;LRP1;IL1B;...
Tuberculosis -1.79 2.21e-2 159/180 (88.33%) FCGR2C;STAT1;CASP3;...
Amino sugar and nucleotide sugar metabolism -1.83 1.41e-2 38/48 (79.17%) CYB5R1;NAGK;HK1;...
Th1 and Th2 cell differentiation -1.85 1.07e-2 80/92 (86.96%) NOTCH2;IL2RA;STAT1;...
Th17 cell differentiation -1.85 1.04e-2 95/107 (88.79%) IL2RA;RARA;STAT1;...
Leishmaniasis -1.87 8.70e-3 67/77 (87.01%) FCGR2C;STAT1;HLA-DRA;...
ECM-receptor interaction -1.88 9.79e-3 80/88 (90.91%) SV2B;ITGB5;ITGA5;...
Phagosome -1.90 9.32e-3 118/152 (77.63%) HLA-DRA;ITGB3;HLA-DOA;...
Bladder cancer -1.92 4.35e-3 40/41 (97.56%) ARAF;MAP2K2;KRAS;...
Hematopoietic cell lineage -1.94 2.61e-3 90/99 (90.91%) IL3RA;CD5;CD19;...
Chagas disease -1.95 3.26e-3 93/102 (91.18%) PLCB4;CD3D;TLR4;...
Graft-versus-host disease -2.00 4.35e-3 32/42 (76.19%) HLA-DRA;HLA-DOA;FAS;...
Inflammatory bowel disease -2.02 6.53e-3 58/65 (89.23%) STAT1;SMAD3;TLR5;...
Primary immunodeficiency -2.08 1.31e-2 33/38 (86.84%) CD19;RAG2;CD8B;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.04uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.04uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.01uM - 2.22uM 24H